Rini Brian I, Campbell Steven C, Rathmell W Kimryn
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.
Curr Opin Oncol. 2006 May;18(3):289-96. doi: 10.1097/01.cco.0000219260.60714.c4.
In this review we will highlight the recent novel contributions to the treatment of renal cell carcinoma in the fields of anti-angiogenesis, immunotherapeutics, and surgical management. In addition, this review will update recent advances in diagnostic and imaging modalities for renal cell carcinoma and dietary and environmental relationships to the epidemiology of this growing disease.
Advancements in the use of innovative treatment strategies for the management of localized renal cell carcinoma and the introduction of new targeted therapeutics with benefit in the metastatic setting has produced a major impact on the treatment of this disease.
The management of metastatic renal cell carcinoma has undergone a revolution in the past year with groundbreaking treatment strategies encompassing a broad range of therapeutic modalities. At the other end of the spectrum, emerging data is beginning to change our perspective about the management of small, localized renal tumors that are being discovered with increasing frequency. This review will update recent findings supporting diet and tobacco exposure as etiologic factors in the development of renal cell carcinoma, the molecular concepts that underlie the disease and the targeted therapeutics designed to inhibit specific kinase activities, and emerging use of minimally invasive therapies for localized disease.
在本综述中,我们将重点介绍抗血管生成、免疫治疗和外科治疗领域中肾细胞癌治疗方面的最新重要进展。此外,本综述将更新肾细胞癌诊断和成像方式的最新进展以及饮食和环境与这种日益常见疾病的流行病学之间的关系。
用于治疗局限性肾细胞癌的创新治疗策略的进展以及在转移性情况下具有益处的新靶向治疗药物的引入,对这种疾病的治疗产生了重大影响。
在过去一年中,转移性肾细胞癌的治疗发生了变革,突破性的治疗策略涵盖了广泛的治疗方式。在另一端,新出现的数据开始改变我们对小的局限性肾肿瘤治疗的看法,这些肿瘤的发现频率越来越高。本综述将更新支持饮食和烟草暴露作为肾细胞癌发病病因因素的最新发现、该疾病的分子概念以及旨在抑制特定激酶活性的靶向治疗药物,以及局部疾病微创治疗的新应用。